From Medical Breakthrough to Global Conversation
Few therapeutic areas have transformed public debate as rapidly as obesity treatments. In just a few years, drugs once known primarily to endocrinologists have become headline news, investor talking points, and social media trends.
GLP-1 medicines, originally developed for diabetes, now sit at the centre of a rapidly expanding global conversation about metabolic health. Scientific breakthroughs, government interventions, corporate competition, and celebrity influence have all contributed to making obesity treatment one of the most closely watched topics across healthcare, business, and policy. But beneath the headlines lies a more complex picture. Media narratives around obesity treatments differ significantly across regions, stakeholders, and companies. Understanding these shifts reveals how the global conversation around metabolic health is evolving. And where it may go next.
Our AI-powered and expert‑interpreted analysis of 15,439 English‑language online news articles (published between January 2025 – February 2026) reveals how governments, companies, innovators and cultural voices are shaping the new obesity‑treatment landscape.
The Rise of GLP-1 Drugs and the Race to Expand Access
GLP-1 therapies have quickly moved from specialist treatments to mainstream awareness.
U.S. attention surged as Medicare/Medicaid became central to the affordability debate — first through Wegovy’s cardiovascular indication opening Medicare Part D coverage for eligible patients, and later through federal pricing-and-access initiatives announced in late 2025 and formalized in subsequent CMS models.
These decisions positioned the United States as the central arena for discussions about affordability, regulation, and patient access.
At the same time, pharmaceutical companies are racing toward the next frontier: oral GLP-1 therapies.
Novo Nordisk’s oral version of Wegovy became the first FDA-approved chronic weight management treatment (December 2025), while Eli Lilly has advanced its own oral candidate, orforglipron (currently pending regulatory decisions), which has generated strong enthusiasm among medical experts. The prospect of convenient, pill-based treatments is expected to expand adoption globally by improving patient adherence and accessibility.
Regional Media Narratives: How the Debate Differs Around the World
Although the obesity treatment boom is global, the way the story unfolds in the media varies widely by region.
North & South America: Policy and Market Competition
Across the Americas, media coverage has been dominated by U.S. regulatory decisions and the intense rivalry between Eli Lilly and Novo Nordisk. Policy debates around pricing and reimbursement have made the region the focal point for discussions about the commercial future of obesity treatments.
Asia-Pacific: Market Expansion and Cultural Influence
In APAC, the narrative has focused more strongly on market growth and accessibility.
India has emerged as a particularly important battleground, as pharmaceutical companies introduce new products, reduce prices, and form partnerships with domestic drug manufacturers while preparing for semaglutide generics to enter the market.
The region has also seen a notable role for cultural influencers. Celebrities, athletes, and public figures across India and South Korea have helped amplify the visibility of weight-loss treatments, bringing the topic into mainstream public discussion.
Europe: Science, Pricing, and Healthcare Systems
European media coverage has largely centred on healthcare systems and scientific progress.
Pricing negotiations, reimbursement policies, and regulatory decisions remain key themes. At the same time, attention has increasingly turned toward next-generation therapies such as amycretin, which could further transform obesity treatment.
Africa: Emerging Public Health Discussions
In Africa, the conversation remains at an earlier stage. Coverage has primarily focused on public health implications and long-term access challenges rather than immediate product launches or competitive developments.
Pharma Competition Intensifies: How Key Companies Shaped the Narrative
Corporate strategy has played a major role in shaping the global media conversation around obesity treatments.
Eli Lilly strengthened its leadership position through record demand for Mounjaro and Zepbound, continued global expansion, and strong investor confidence. Progress with its oral drug candidate orforglipron has reinforced expectations of sustained leadership in the market.
Novo Nordisk, long seen as a pioneer in GLP-1 therapies, has entered a transitional phase. The company is advancing oral semaglutide and investing in next-generation assets such as amycretin while navigating growing pricing pressure and competition, particularly in Europe and India.
Several other pharmaceutical companies are now moving aggressively into the obesity market.
- Roche plans to being late-stage trials of CT-388 and partners with Zealand Pharma to develop petrelintide, an amylin analog positioned as a potential alternative to GLP-1 therapies.
- Pfizer pivoted strategically after discontinuing its oral candidate danuglipron, pursuing acquisitions such as the multibillion-dollar purchase of Metsera to re-enter the obesity space.
- Amgen has focused on differentiation through MariTide, a monthly injection showing promising weight-loss results that could compete with existing weekly treatments.
Taken together, these developments signal that the obesity treatment market is evolving from a duopoly toward a broader, highly competitive innovation race.
Celebrity Influence and Social Media Amplification
The narrative around obesity treatments has not been shaped by science and policy alone.
High-profile figures such as Oprah Winfrey, Elon Musk, and Serena Williams have helped bring GLP-1 drugs into mainstream public awareness. Meanwhile, athletes and celebrities across Asia have played a similar role in regional discussions.
Social media has further amplified the conversation. Platforms such as TikTok are filled with personal stories from individuals documenting their experiences with weight-loss medications.
While this visibility has helped increase awareness of obesity as a medical condition, it has also created new challenges. Viral narratives can sometimes oversimplify treatment outcomes, leaving healthcare professionals to address misconceptions about the speed and sustainability of results.
Media Sentiment: What the Data Reveals
We analysed media sentiment at the level of the company, using Commetric’s SieraPlex signals and in-house transformer-based sentiment models specifically designed for pharma and healthcare conversations.
Media sentiment toward companies involved in obesity treatments has remained largely positive or neutral.
Among the major pharmaceutical players, Roche and Eli Lilly have achieved the strongest balance of positive coverage. Negative mentions remain relatively limited overall and are typically linked to innovation setbacks or leadership scrutiny.
Conversely, coverage related to regulatory approvals, clinical trial milestones, corporate leadership developments, and financial performance tends to generate the most favourable sentiment.
These patterns highlight how specific types of news events continue to shape the tone of media narratives across the pharmaceutical sector.
Media Volume vs Audience Resonance: Two Different Signals
Another important distinction emerges when comparing overall news volume with social amplification. While regulatory announcements, pricing decisions, and corporate financial results tend to generate the largest spikes in media coverage, they are not always the stories that resonate most strongly with audiences.
By plotting online news volume against social sharing activity, it becomes clear that narratives involving celebrity experiences, personal transformation stories, and broader lifestyle debates around weight-loss drugs often generate disproportionate engagement across platforms such as X, Facebook, and Reddit.
In other words, policy and corporate developments tend to drive the news cycle, while human-interest narratives and cultural conversations are more likely to cut through the noise and travel across social networks. One topic, however, consistently bridges both dynamics: pricing. As affordability and access become central to the public debate around GLP-1 treatments, pricing discussions are increasingly capable of generating both sustained media coverage and strong audience engagement.
For communications and public affairs professionals, this underscores the importance of aligning messaging with the stakeholders shaping these conversations: from policymakers and healthcare providers to investors, patient groups, and the wider public.
The Future of the Obesity Treatment Market
One conclusion is clear: obesity has firmly emerged as a global therapeutic priority.
Scientific innovation, expanding treatment access, and increasing public awareness are accelerating the pace of change across the healthcare ecosystem. As oral medications reach the market and next-generation mechanisms advance through clinical trials, competition among pharmaceutical companies is set to intensify further.
What began as a two-company race is quickly evolving into a broader ecosystem of scientific innovation, commercial strategy, and public debate.
Why Media Narratives Matter in the GLP-1 Era
For healthcare companies, policymakers, and communications leaders, understanding how these narratives evolve is becoming increasingly important.
Media coverage does more than reflect developments in the obesity treatment market: it actively shapes public perceptions, investor expectations, and policy debates. Tracking which topics dominate the conversation, which stakeholders drive influence, and how sentiment shifts across markets can reveal emerging risks and opportunities long before they become widely visible.
Advanced media analytics makes it possible to map these complex reputation dynamics across global media ecosystems. By combining AI-powered analysis with expert interpretation, organisations can move beyond simple monitoring to uncover the deeper forces shaping industry narratives and make more confident, business-critical decisions.
Our approach: combining AI-powered analysis with expert interpretation
Data period: 14 months / 01 January 2025 – 28 February 2026
Language: English
Media channel: online news media via Opoint Technologies
Sampling strategy: headline mentions of obesity or weight loss or slimming, in association with synonyms of drug, treatment, medication.
Data enrichment steps
- Content cleanup via in-house machine learning models for earned media content discovery, removing press release syndication
- SieraPlex identifies companies, maps them to business events and company-centric sentiment, and supports competitor intelligence insights.
- Sentiment model: media sentiment at the level of the company, using Commetric’s SieraPlex signals and in-house transformer-based sentiment models specifically designed for pharma and healthcare media conversations.
- Named entity recognition module extracts names of key opinion leaders and commentators
- Topic modelling to extract key topics of general conversations
- Metadata fields used in reporting: country / region data based on geo-location of publisher; social amplification data via third-parties (covers link shares on X, Facebook and reddit)